Atlas Trials

A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment

Clinical trial NCT05241834 · COMPLETED

Trial details

NCT number
NCT05241834
Sponsor
Eli Lilly and Company
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Carcinoma, Non-Small-Cell LungThyroid Neoplasms
Start date
2022-03-23
Primary completion
2024-09-17
Enrollment
70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.